Julie is a seasoned professional with over a decade of experience in the pharmaceutical and biotechnology industries. She first discovered her passion for oncology and rare disease treatments at university and has since developed deep expertise, promoting access to cutting-edge therapies that bring hope and a better quality of life to thousands of suffering people.
With an MBA in Pharmaceutical Management and a B.Sc. in Biochemistry, Julie stays abreast of scientific and medical breakthroughs; she develops effective market access strategies for innovative treatments, particularly in the field of rare diseases; and knows how to implement perfectly targeted initiatives. Julie is well-acquainted with the reality of pharmaceutical companies and has a thorough understanding of the complex dynamics of the industry, having notably acted as a leader in the management of Canadian portfolios on a global scale. Her expertise encompasses a comprehensive evaluation of market access, including business development and pre- and post-commercialization strategies.
Julie is recognized for developing customized submissions that meet Canadian reimbursement criteria with ease and has spearheaded several proposals submitted to Health Technology Assessors, such as CADTH and INESSS. She has also implemented negotiation strategies with pan-Canadian Pharmaceutical Alliance (pCPA) in addition to provincial payers and private insurers.
Without a doubt, Julie’s prowess in the pharmaceutical industry makes her the consultant of choice: she is familiar with pricing strategies; navigates smoothly through the nuances and specificities of various provincial regulations; masters competitive list prices; and ensures compliance with PMPRB regulations. Her wide range of skills allow her to provide well-thought-out solutions that
keep pace with the ever-changing health care landscape, earning her the trust and recognition of her peers and clients.
